<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295893</url>
  </required_header>
  <id_info>
    <org_study_id>05015</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CDR0000455631</secondary_id>
    <nct_id>NCT00295893</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer</brief_title>
  <official_title>Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving more than one&#xD;
      drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as&#xD;
      trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells&#xD;
      to grow and spread. Others find tumor cells and help kill them or carry tumor-killing&#xD;
      substances to them. Giving combination chemotherapy with or without trastuzumab before&#xD;
      surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be&#xD;
      removed. It is not yet known whether combination chemotherapy is more effective with or&#xD;
      without trastuzumab in treating breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is comparing two different regimens of combination&#xD;
      chemotherapy given together with or without trastuzumab to see how well they work in treating&#xD;
      patients with stage II or stage III breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare 2 neoadjuvant chemotherapy regimens (docetaxel, doxorubicin hydrochloride, and&#xD;
           cyclophosphamide [TAC] vs doxorubicin and cyclophosphamide followed by paclitaxel and&#xD;
           carboplatin [ACAC]), in terms of toxicities and effectiveness as defined by the&#xD;
           pathological complete remission rate, in patients with non HER2/neu overexpressing stage&#xD;
           II or III breast cancer.&#xD;
&#xD;
        -  Evaluate the probability of achieving a pathological complete remission when adding&#xD;
           trastuzumab (Herceptin®) to ACAC in the subset of patients with HER2/neu overexpressing&#xD;
           stage II or III breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Identify prognostic and predictive markers of outcome, recurrence, and targets of&#xD;
           therapy.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients with non HER2/neu overexpressing tumors are&#xD;
      randomized to 1 of 2 treatment arms. Patients with HER2/neu overexpressing tumors are&#xD;
      assigned to arm III.&#xD;
&#xD;
        -  Arm I: Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel&#xD;
           IV on day 1. Treatment repeats every 21 days for 6 courses.&#xD;
&#xD;
        -  Arm II: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1;&#xD;
           treatment repeats every 2 weeks for 4 courses. Patients then receive carboplatin IV on&#xD;
           day 1 and paclitaxel IV on days 1, 8, and 15; treatment with carboplatin and paclitaxel&#xD;
           repeats every 4 weeks for 3 courses.&#xD;
&#xD;
        -  Arm III: Patients receive chemotherapy as in arm II. They also receive trastuzumab&#xD;
           (Herceptin®) IV weekly, beginning with the first doses of paclitaxel and carboplatin.&#xD;
&#xD;
      Within 4 weeks after completion of chemotherapy with or without trastuzumab (Herceptin®), all&#xD;
      patients undergo surgery.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 105 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 14, 2005</start_date>
  <completion_date type="Anticipated">December 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>At the time of surgery within 4 weeks of the end of chemotherapy</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>At the time of surgery within 4 weeks of the end of chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life and neuropathy assessment of prognostic and predictive markers as measured by FACT exploratory methods at 1 year</measure>
    <time_frame>1 year post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV on day 1. Treatment repeats every 21 days for 6 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; treatment repeats every 2 weeks for 4 courses. Patients then receive carboplatin IV on day 1 and paclitaxel IV on days 1, 8, and 15; treatment with carboplatin and paclitaxel repeats every 4 weeks for 3 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive chemotherapy as in arm II. They also receive trastuzumab (Herceptin®) IV weekly, beginning with the first doses of paclitaxel and carboplatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven infiltrating ductal or lobular breast carcinoma&#xD;
&#xD;
               -  Stage II or III disease&#xD;
&#xD;
               -  Inflammatory breast cancer allowed&#xD;
&#xD;
          -  Hormone-receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status &lt; 2&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Menopausal status not specified (for female patients)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal (except for patient's with Gilbert's disease)&#xD;
&#xD;
          -  Creatinine ≤ 1.2 mg/dL&#xD;
&#xD;
          -  Creatinine clearance ≥ 70 mL/min&#xD;
&#xD;
          -  Ejection fraction ≥ 50% on MUGA&#xD;
&#xD;
          -  No neuropathy ≥ grade 1&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective nonhormonal contraception&#xD;
&#xD;
          -  No prior malignant disease within the past 5 years, excluding:&#xD;
&#xD;
               -  Squamous cell or basal cell skin carcinoma&#xD;
&#xD;
               -  Stage I or in situ cervical carcinoma&#xD;
&#xD;
          -  No noninvasive (in situ) breast carcinoma within the past 5 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 5 years since prior antiestrogen treatment for any indication other than&#xD;
             breast cancer prevention (tamoxifen, raloxifene, or an aromatase inhibitor)&#xD;
&#xD;
          -  No prior radiotherapy to the chest wall&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Mortimer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammatory breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>Paget disease of the breast with invasive ductal carcinoma</keyword>
  <keyword>invasive ductal breast carcinoma with predominant intraductal component</keyword>
  <keyword>invasive ductal breast carcinoma</keyword>
  <keyword>medullary ductal breast carcinoma with lymphocytic infiltrate</keyword>
  <keyword>comedo ductal breast carcinoma</keyword>
  <keyword>invasive lobular breast carcinoma with predominant in situ component</keyword>
  <keyword>invasive lobular breast carcinoma</keyword>
  <keyword>mucinous ductal breast carcinoma</keyword>
  <keyword>papillary ductal breast carcinoma</keyword>
  <keyword>tubular ductal breast carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

